PortalPublikationenLymphocytopenia and Anti-CD38 Directed Treatment Impact the ...

Lymphocytopenia and Anti-CD38 Directed Treatment Impact the Serological SARS-CoV-2 Response after Prime Boost Vaccination in Patients with Multiple Myeloma

Standard

Lymphocytopenia and Anti-CD38 Directed Treatment Impact the Serological SARS-CoV-2 Response after Prime Boost Vaccination in Patients with Multiple Myeloma. / Ghandili, Susanne; Schönlein, Martin; Wiessner, Christian; Becher, Heiko; Lütgehetmann, Marc; Brehm, Thomas Theo; Wiesch, Julian Schulze zur; Bokemeyer, Carsten; Sinn, Marianne; Weisel, Katja C.; Leypoldt, Lisa.

in: J CLIN MED, Jahrgang 10, Nr. 23, 5499, 24.11.2021.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Ghandili, S, Schönlein, M, Wiessner, C, Becher, H, Lütgehetmann, M, Brehm, TT, Wiesch, JSZ, Bokemeyer, C, Sinn, M, Weisel, KC & Leypoldt, L 2021, 'Lymphocytopenia and Anti-CD38 Directed Treatment Impact the Serological SARS-CoV-2 Response after Prime Boost Vaccination in Patients with Multiple Myeloma', J CLIN MED, Jg. 10, Nr. 23, 5499. https://doi.org/10.3390/jcm10235499, https://doi.org/10.3390/jcm10235499

APA

Ghandili, S., Schönlein, M., Wiessner, C., Becher, H., Lütgehetmann, M., Brehm, T. T., Wiesch, J. S. Z., Bokemeyer, C., Sinn, M., Weisel, K. C., & Leypoldt, L. (2021). Lymphocytopenia and Anti-CD38 Directed Treatment Impact the Serological SARS-CoV-2 Response after Prime Boost Vaccination in Patients with Multiple Myeloma. J CLIN MED, 10(23), [5499]. https://doi.org/10.3390/jcm10235499, https://doi.org/10.3390/jcm10235499

Vancouver

Ghandili S, Schönlein M, Wiessner C, Becher H, Lütgehetmann M, Brehm TT et al. Lymphocytopenia and Anti-CD38 Directed Treatment Impact the Serological SARS-CoV-2 Response after Prime Boost Vaccination in Patients with Multiple Myeloma. J CLIN MED. 2021 Nov 24;10(23). 5499. https://doi.org/10.3390/jcm10235499, https://doi.org/10.3390/jcm10235499

Bibtex

@article{05e8c38ee0b24f94b5b30a03ef5c6a3c,
title = "Lymphocytopenia and Anti-CD38 Directed Treatment Impact the Serological SARS-CoV-2 Response after Prime Boost Vaccination in Patients with Multiple Myeloma",
abstract = "Even though several SARS-CoV-2 vaccines have shown high effectiveness in the prevention of COVID-19 in healthy subjects, vaccination response in patients with plasma-cell-related disorders (PCD) remains widely unknown. Here, we report on an analysis describing the serological response after prime-boost SARS-CoV-2 vaccination in PCD patients, as compared to a healthy control group, and on possible influencing factors of serological responses. Blood samples were analyzed for the presence of quantitative anti-SARS-CoV-2 spike RBD Ig. A total of 82 patients were included; 67 received mRNA-, eight vector-based and four heterologous vaccinations. SARS-CoV-2 antibody titers (SP-AbT) were assessed in a mean of 23 days (SD ± 11 days) after the first and in a mean 21 days (SD ± 9) after prime-boost vaccination. A positive SP-AbT was detected in 31.9% of PCD patients after the first vaccination, and in 88.9% (44/49) after prime-boost vaccination, which was significantly less likely than that in the control group (100%, 78/78) (p = 0.008). Furthermore, we have been able to validate our previously suggested threshold of 30 CD19+ B lymphocytes/µL as being predictive for SP-AbT development. Despite anti-CD38 directed therapy, quadruplet treatment, higher age and missing deep remission, which correlated negatively with SP-AbT appearance, SP-AbT formation is possible in a majority of myeloma patients after prime-boost vaccination.",
author = "Susanne Ghandili and Martin Sch{\"o}nlein and Christian Wiessner and Heiko Becher and Marc L{\"u}tgehetmann and Brehm, {Thomas Theo} and Wiesch, {Julian Schulze zur} and Carsten Bokemeyer and Marianne Sinn and Weisel, {Katja C.} and Lisa Leypoldt",
year = "2021",
month = nov,
day = "24",
doi = "10.3390/jcm10235499",
language = "English",
volume = "10",
journal = "J CLIN MED",
issn = "2077-0383",
publisher = "MDPI AG",
number = "23",

}

RIS

TY - JOUR

T1 - Lymphocytopenia and Anti-CD38 Directed Treatment Impact the Serological SARS-CoV-2 Response after Prime Boost Vaccination in Patients with Multiple Myeloma

AU - Ghandili, Susanne

AU - Schönlein, Martin

AU - Wiessner, Christian

AU - Becher, Heiko

AU - Lütgehetmann, Marc

AU - Brehm, Thomas Theo

AU - Wiesch, Julian Schulze zur

AU - Bokemeyer, Carsten

AU - Sinn, Marianne

AU - Weisel, Katja C.

AU - Leypoldt, Lisa

PY - 2021/11/24

Y1 - 2021/11/24

N2 - Even though several SARS-CoV-2 vaccines have shown high effectiveness in the prevention of COVID-19 in healthy subjects, vaccination response in patients with plasma-cell-related disorders (PCD) remains widely unknown. Here, we report on an analysis describing the serological response after prime-boost SARS-CoV-2 vaccination in PCD patients, as compared to a healthy control group, and on possible influencing factors of serological responses. Blood samples were analyzed for the presence of quantitative anti-SARS-CoV-2 spike RBD Ig. A total of 82 patients were included; 67 received mRNA-, eight vector-based and four heterologous vaccinations. SARS-CoV-2 antibody titers (SP-AbT) were assessed in a mean of 23 days (SD ± 11 days) after the first and in a mean 21 days (SD ± 9) after prime-boost vaccination. A positive SP-AbT was detected in 31.9% of PCD patients after the first vaccination, and in 88.9% (44/49) after prime-boost vaccination, which was significantly less likely than that in the control group (100%, 78/78) (p = 0.008). Furthermore, we have been able to validate our previously suggested threshold of 30 CD19+ B lymphocytes/µL as being predictive for SP-AbT development. Despite anti-CD38 directed therapy, quadruplet treatment, higher age and missing deep remission, which correlated negatively with SP-AbT appearance, SP-AbT formation is possible in a majority of myeloma patients after prime-boost vaccination.

AB - Even though several SARS-CoV-2 vaccines have shown high effectiveness in the prevention of COVID-19 in healthy subjects, vaccination response in patients with plasma-cell-related disorders (PCD) remains widely unknown. Here, we report on an analysis describing the serological response after prime-boost SARS-CoV-2 vaccination in PCD patients, as compared to a healthy control group, and on possible influencing factors of serological responses. Blood samples were analyzed for the presence of quantitative anti-SARS-CoV-2 spike RBD Ig. A total of 82 patients were included; 67 received mRNA-, eight vector-based and four heterologous vaccinations. SARS-CoV-2 antibody titers (SP-AbT) were assessed in a mean of 23 days (SD ± 11 days) after the first and in a mean 21 days (SD ± 9) after prime-boost vaccination. A positive SP-AbT was detected in 31.9% of PCD patients after the first vaccination, and in 88.9% (44/49) after prime-boost vaccination, which was significantly less likely than that in the control group (100%, 78/78) (p = 0.008). Furthermore, we have been able to validate our previously suggested threshold of 30 CD19+ B lymphocytes/µL as being predictive for SP-AbT development. Despite anti-CD38 directed therapy, quadruplet treatment, higher age and missing deep remission, which correlated negatively with SP-AbT appearance, SP-AbT formation is possible in a majority of myeloma patients after prime-boost vaccination.

UR - https://www.mdpi.com/2077-0383/10/23/5499

U2 - 10.3390/jcm10235499

DO - 10.3390/jcm10235499

M3 - SCORING: Journal article

C2 - 34884200

VL - 10

JO - J CLIN MED

JF - J CLIN MED

SN - 2077-0383

IS - 23

M1 - 5499

ER -